Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Conaway

Showing results (11-20 of 128) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
The Role of Early-Phase Design-ResponseMark R Conaway, Gina R Petroni
Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses|June 28, 2013
Relationship of glucose values to sliding scale insulin (correctional insulin) dose delivery and meal time in acute care patients with diabetes mellitusBarbara Trotter, Mark R Conaway, Suzanne M Burns
Statistics in Medicine|July 19, 2012
Using the time-to-event continual reassessment method in the presence of partial ordersNolan A Wages, Mark R Conaway, John O'Quigley
Biometrics|March 3, 2011
Continual reassessment method for partial orderingNolan A Wages, Mark R Conaway, John O'Quigley
JNCI Cancer Spectrum|June 18, 2019
Consequences of Performing Parallel Dose Finding Trials in Heterogeneous Groups of PatientsBethany Jablonski Horton, John O'Quigley, Mark R Conaway
Stroke|November 5, 2011
Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic strokePooja Khatri, Mark R Conaway, Karen C Johnston, et al.
Clinical Trials (London, England)|October 3, 2013
Performance of two-stage continual reassessment method relative to an optimal benchmarkNolan A Wages, Mark R Conaway, John O'Quigley
Biometrics|September 2, 2004
Designs for single- or multiple-agent phase I trialsMark R Conaway, Stephanie Dunbar, Shyamal D Peddada
Statistics in Medicine|October 12, 2013
Phase I design for completely or partially ordered treatment schedulesNolan A Wages, John O'Quigley, Mark R Conaway
Clinical Trials (London, England)|June 10, 2011
Dose-finding design for multi-drug combinationsNolan A Wages, Mark R Conaway, John O'Quigley
Pageof 13

Showing results (11-20 of 128) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2019
The Role of Early-Phase Design-ResponseMark R Conaway, Gina R Petroni
Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses|June 28, 2013
Relationship of glucose values to sliding scale insulin (correctional insulin) dose delivery and meal time in acute care patients with diabetes mellitusBarbara Trotter, Mark R Conaway, Suzanne M Burns
Statistics in Medicine|July 19, 2012
Using the time-to-event continual reassessment method in the presence of partial ordersNolan A Wages, Mark R Conaway, John O'Quigley
Biometrics|March 3, 2011
Continual reassessment method for partial orderingNolan A Wages, Mark R Conaway, John O'Quigley
JNCI Cancer Spectrum|June 18, 2019
Consequences of Performing Parallel Dose Finding Trials in Heterogeneous Groups of PatientsBethany Jablonski Horton, John O'Quigley, Mark R Conaway
Stroke|November 5, 2011
Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic strokePooja Khatri, Mark R Conaway, Karen C Johnston, et al.
Clinical Trials (London, England)|October 3, 2013
Performance of two-stage continual reassessment method relative to an optimal benchmarkNolan A Wages, Mark R Conaway, John O'Quigley
Biometrics|September 2, 2004
Designs for single- or multiple-agent phase I trialsMark R Conaway, Stephanie Dunbar, Shyamal D Peddada
Statistics in Medicine|October 12, 2013
Phase I design for completely or partially ordered treatment schedulesNolan A Wages, John O'Quigley, Mark R Conaway
Clinical Trials (London, England)|June 10, 2011
Dose-finding design for multi-drug combinationsNolan A Wages, Mark R Conaway, John O'Quigley
Pageof 13